Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Lung Transplantation
68%
Belatacept
18%
Bridge to Lung Transplantation
18%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
15%
Chronic Lung Allograft Dysfunction
13%
Lung
13%
Immunosuppression
12%
Lung Disease
10%
Single Center
10%
Houston
10%
Methodist
10%
Liver
9%
Heparin Management
9%
ProtekDuo
9%
Pulmonary Cement Embolism
9%
Pilot Randomized Controlled Trial
9%
Adult Patients
9%
Extracorporeal Life Support
9%
Clinical Recovery
9%
AIDS/HIV
9%
Bilateral Lung Transplantation
9%
Madness
9%
Respiratory Failure
9%
COVID-19
9%
Pretransplant
9%
Scleroderma
9%
Heart-lung Transplant
9%
Venovenous
9%
Methacholine Challenge
9%
Risk Model
9%
Bivalirudin
9%
Pregnant Women
9%
Vasoactive Intestinal Peptide
9%
Instrument Validation
9%
Risk Assessment
9%
Long-term Survival
9%
Transplantation
7%
Validation Cohort
6%
High Risk
6%
Liver Transplant Recipients
6%
Restrictive Lung Disease
5%
Double Lung Transplant
5%
Medicine and Dentistry
Lung Transplantation
100%
Lung
29%
Belatacept
18%
Allograft
13%
Extracorporeal Membrane Oxygenation
12%
Immunosuppressive Treatment
12%
Silo-Filler's Disease
11%
Bivalirudin
9%
Scleroderma
9%
Randomized Controlled Trial
9%
Heparin
9%
Methacholine
9%
Extracorporeal
9%
Long Term Survival
9%
Provocation Test
9%
Patient with Human Immunodeficiency Virus
9%
COVID-19
9%
Respiratory Failure
9%
Vasoactive Intestinal Polypeptide
9%
Cryopreservation
9%
Heart Muscle Ischemia
9%
Arm
6%
Hazard Ratio
5%
Diseases
5%
Patient Population
5%
Infection
5%
